Mitochondrial Peptides: What MOTS-c and SS-31 Research Actually Measures

MOTS-c and SS-31 are both described as mitochondrial peptides, which obscures the fact that they do entirely different things. One is a signalling molecule encoded by mitochondrial DNA; the other is a synthetic compound that binds a specific inner-membrane lipid. Their literatures barely overlap.

MOTS-c: a mitochondrial-derived peptide

MOTS-c is encoded within the mitochondrial 12S rRNA gene — a short open reading frame in mitochondrial DNA rather than nuclear DNA. That makes it one of a small class of mitochondrial-derived peptides.

Lee and colleagues characterised its receptor-signalling action, measuring inhibition of the folate–methionine cycle and de novo purine biosynthesis, with consequent AMPK activation, in mouse skeletal muscle and cultured cells (Cell Metab, 2015; PMID 25738459). The mechanism is indirect: MOTS-c perturbs a receptor-signalling cycle, and AMPK responds to the resulting shift in energy state.

A later paper established that it also acts in the nucleus. Kim and colleagues measured AMPK-dependent nuclear translocation under receptor-signalling stress in cultured human cells, and occupancy at antioxidant-response-element genes together with interaction with NRF2 (Cell Metab, 2018; PMID 29983246). A mitochondrially encoded peptide regulating nuclear gene expression is the notable claim here.

Reynolds and colleagues examined age-related endpoints, measuring transcriptomic and metabolomic profiles alongside physical-function assays in young, middle-aged and old CD-1 and C57BL/6 mice (Nat Commun, 2021; PMID 33473109).

SS-31: a cardiolipin-binding compound

SS-31 (elamipretide) is a synthetic tetrapeptide with an alternating aromatic-cationic motif. It concentrates in the inner mitochondrial membrane without requiring a membrane potential — unusual, and the basis of its selectivity.

Zhao and colleagues measured intracellular ROS, mitochondrial swelling, ROS-induced calcium influx and membrane depolarisation in neuronal cells and isolated mitochondria at nanomolar concentrations (J Biol Chem, 2004; PMID 15178689).

The mechanism was resolved later. Birk and colleagues measured high-affinity binding of a fluorescent SS-31 analogue to cardiolipin, inhibition of cytochrome c peroxidase activity, and cristae ultrastructure in ischaemic rat kidney (J Am Soc Nephrol, 2013; PMID 23813215). Cardiolipin is a phospholipid largely confined to the inner mitochondrial membrane, which explains the targeting.

Mitchell and colleagues refined this further, measuring interfacial partitioning as a function of bilayer surface charge, lipid packing and surface electrostatics in model membranes and isolated mitochondria (J Biol Chem, 2020; PMID 32273339).

Reading the two together

Because the readouts differ, an assay designed for one will often show nothing for the other. That is a property of the mechanisms, not evidence of inactivity.

Cardiolipin, and why a lipid is the target

SS-31’s mechanism only makes sense once cardiolipin is understood as a structural component rather than an incidental lipid. Cardiolipin is a dimeric phospholipid with four acyl chains and a small head group, found almost exclusively in the inner mitochondrial membrane. That geometry — a large hydrophobic volume under a narrow head — gives it a conical shape, and conical lipids favour curved membranes. The tightly folded cristae of the inner membrane depend on it.

Cardiolipin also acts as a molecular glue for the electron transport chain. Complexes I, III and IV assemble into supercomplexes, and cardiolipin occupies interface sites between them. When cardiolipin is depleted, oxidised or remodelled abnormally, supercomplexes destabilise, electron transfer becomes less efficient, and electron leak to oxygen rises — producing more reactive oxygen species from the same substrate load. Cytochrome c is also held at the membrane partly by cardiolipin, so cardiolipin peroxidation releases it into the intermembrane space, a proximal step in intrinsic apoptosis.

A compound that binds cardiolipin and stabilises its interactions therefore acts upstream of ROS production rather than scavenging ROS after the fact. That distinction matters when designing controls: an antioxidant comparator and a cardiolipin-binding compound should behave differently in a well-designed assay, and if they do not, the assay is probably reporting something else.

Mitochondrial-derived peptides as a class

MOTS-c belongs to a small group of peptides encoded within mitochondrial DNA rather than the nuclear genome. Humanin, encoded in the 16S rRNA gene, was the first described. The small humanin-like peptides (SHLP1 through SHLP6) followed, also from the 16S region. MOTS-c is encoded in the 12S rRNA gene.

Two features make this class awkward to study and worth handling carefully:

• Short open reading frames within rRNA genes. The coding sequences overlap functional RNA genes, so genetic manipulation of the peptide cannot easily be separated from disruption of the rRNA.
• Low and variable endogenous abundance. Reported circulating concentrations differ substantially between methods, and antibody-based detection in this class has a documented specificity problem. Mass-spectrometric quantitation is the more defensible approach.

The practical consequence for study design is that exogenous-addition experiments carry most of the published weight, and that the concentrations used in those experiments are frequently well above anything measured endogenously. Whether a result reflects physiology or pharmacology is a question worth stating explicitly rather than leaving implied.

Measuring mitochondrial function

Both compounds are usually assessed through the same core panel, and each readout has a characteristic failure mode.

• Extracellular flux (Seahorse-type) respirometry. Oxygen consumption rate under sequential inhibitor injection yields basal respiration, ATP-linked respiration, proton leak, maximal capacity and spare capacity. Highly informative and highly sensitive to cell number per well, so seeding density must be normalised and reported.
• High-resolution respirometry on permeabilised cells or isolated mitochondria. Substrate-uncoupler-inhibitor titration protocols separate complex-specific contributions in a way intact-cell assays cannot.
• Membrane potential. TMRM in non-quench mode, or JC-1. Both are potential-dependent dyes and both are confounded by changes in dye loading; a depolarising control such as FCCP is not optional.
• Reactive oxygen species. MitoSOX for mitochondrial superoxide, roGFP or HyPer for compartment-specific redox state. MitoSOX signal is itself potential-dependent, which is a well-documented trap when the intervention under test also changes membrane potential.
• Supercomplex assembly. Blue-native PAGE with in-gel activity staining, or complexome profiling by mass spectrometry.
• Cristae ultrastructure. Transmission electron microscopy, or expansion or super-resolution microscopy for larger sample numbers.
• AMPK activation. Phospho-Thr172 immunoblot with total AMPK, plus a downstream substrate such as phospho-ACC. A phospho-AMPK band alone is weak evidence; the downstream substrate is what shows the kinase was actually active.

Handling, stability and reconstitution

The two compounds behave very differently in the vial, and treating them alike is a common source of irreproducibility.

• MOTS-c is a 16-residue peptide with no unusual protecting groups. It is water-soluble, and like most unmodified peptides of that length it is susceptible to serum and cell-surface peptidases in culture — which means effective exposure in a long incubation is not the nominal concentration. Repeat dosing or serum-free intervals are the usual mitigations, and either choice should be reported.
• SS-31 is a tetrapeptide with an alternating aromatic-cationic motif and a D-amino acid, making it considerably more protease-resistant. Its cationic character means it adsorbs to plastic and glass; low-binding tubes and carrier protein in dilution buffers reduce loss, which at nanomolar working concentrations is otherwise substantial.

Both are handled cold, reconstituted in an appropriate buffer, aliquoted so that no vial is thawed twice, and protected from light. Stability under the specific storage conditions in use is something to verify rather than assume, particularly where a study runs for weeks from a single reconstitution. Documentation practice is covered separately in keeping a peptide inventory.

Analytical characterisation

Mitochondrial readouts are sensitive and low-concentration, which makes them unusually vulnerable to a concentration error in the stock.

• RP-HPLC purity at a stated wavelength, with the gradient and column reported, so that closely eluting deletion sequences are not hidden by a shallow gradient.
• Mass confirmation by ESI-MS or MALDI-TOF against the calculated mass. For a short peptide the expected mass is unambiguous, which makes this a strong check.
• Net peptide content. The single most common source of a systematically wrong concentration. Lyophilised material carries counterions and residual water; weighing the vial contents without a net-content figure can overstate peptide mass by a fifth or more.
• Counterion identity. Trifluoroacetate carried over from purification is itself biologically active in some cell assays, and is a recognised confounder in mitochondrial and cell-viability work specifically. Acetate-exchanged material avoids the question.

On what a certificate of analysis does and does not establish, see third-party versus in-house peptide testing.

Designing a comparison that means something

If the intention is to run both compounds in one study, the design has to accommodate the fact that they act at different levels.

• Choose readouts that can distinguish them. A ROS endpoint alone will not: one compound may reduce ROS by stabilising the membrane, the other by altering metabolic flux upstream. Pair a structural readout (supercomplex assembly, cristae morphology) with a flux readout (respirometry) and a signalling readout (AMPK and a downstream substrate).
• Match the stress model to the mechanism. Cardiolipin-directed effects show most clearly under conditions that damage the inner membrane; signalling-directed effects show most clearly under metabolic stress. A single model will flatter one and understate the other.
• Include a scavenger comparator. A conventional antioxidant separates mechanism-specific effects from general redox buffering.
• Control the concentration range. SS-31 is active at nanomolar concentrations in the cited work; MOTS-c is typically used at micromolar. Testing both across one shared range guarantees at least one is being used outside its informative window.
• Normalise to mitochondrial content. Citrate synthase activity or mtDNA copy number, so that an apparent change in respiration is not simply a change in how many mitochondria are present.

Where the literature is thin

Being explicit about the gaps is more useful than overstating the record. Endogenous MOTS-c concentrations remain method-dependent and contested. The MOTS-c receptor-signalling mechanism is inferred from downstream consequences rather than a resolved binding event. For SS-31, the cardiolipin interaction is well supported biophysically, but the step from stabilised supercomplexes to a given tissue-level outcome involves several inferences, and much of the in vivo work is in acute injury models whose relationship to chronic states is not established. Nearly all of the cited work is in isolated mitochondria, cultured cells or rodents.

Terms used here

• Cardiolipin — dimeric phospholipid of the inner mitochondrial membrane; supports cristae curvature and supercomplex assembly.
• Cristae — the folds of the inner membrane that house the electron transport chain.
• Supercomplex — higher-order assembly of respiratory chain complexes, thought to improve electron transfer efficiency.
• Proton leak — oxygen consumption not coupled to ATP synthesis.
• Spare respiratory capacity — the difference between maximal and basal respiration; a common stress-reserve metric.
• AMPK — AMP-activated protein kinase, a cellular energy sensor activated by a rising AMP:ATP ratio.
• Mitochondrial-derived peptide — a peptide encoded in mitochondrial rather than nuclear DNA.

For related background on how peptide modifications change stability and duration, see peptide half-life and analog modifications, and on naming conventions across analogs and fragments, peptide nomenclature.

Browse Mitochondrial & Cellular Compounds.

All findings cited are from in vitro or animal models. All products referenced are supplied for laboratory research use only and are not approved for human consumption, clinical, or veterinary use.